TY  - JOUR
A1  - Vogt, Marius
A1  - Girschick, Hermann
A1  - Schweitzer, Tilmann
A1  - Benoit, Clemens
A1  - Holl-Wieden, Annette
A1  - Seefried, Lothar
A1  - Jakob, Franz
A1  - Hofmann, Christine
T1  - Pediatric hypophosphatasia: lessons learned from a retrospective single-center chart review of 50 children
JF  - Orphanet Journal of Rare Diseases
N2  - Background 
Hypophosphatasia (HPP) is a rare, inherited metabolic disorder caused by loss-of-function mutations in the ALPL gene that encodes the tissue-nonspecific alkaline phosphatase TNAP (ORPHA 436). Its clinical presentation is highly heterogeneous with a remarkably wide-ranging severity. HPP affects patients of all ages. In children HPP-related musculoskeletal symptoms may mimic rheumatologic conditions and diagnosis is often difficult and delayed. To improve the understanding of HPP in children and in order to shorten the diagnostic time span in the future we studied the natural history of the disease in our large cohort of pediatric patients. This single centre retrospective chart review included longitudinal data from 50 patients with HPP diagnosed and followed at the University Children's Hospital Wuerzburg, Germany over the last 25 years. 

Results 
The cohort comprises 4 (8%) perinatal, 17 (34%) infantile and 29 (58%) childhood onset HPP patients. Two patients were deceased at the time of data collection. Diagnosis was based on available characteristic clinical symptoms (in 88%), low alkaline phosphatase (AP) activity (in 96%), accumulating substrates of AP (in 58%) and X-ray findings (in 48%). Genetic analysis was performed in 48 patients (31 compound heterozygous, 15 heterozygous, 2 homozygous mutations per patient), allowing investigations on genotype-phenotype correlations. Based on anamnestic data, median age at first clinical symptoms was 3.5 months (min. 0, max. 107), while median time to diagnosis was 13 months (min. 0, max. 103). Common symptoms included: impairment of motor skills (78%), impairment of mineralization (72%), premature loss of teeth (64%), musculoskeletal pain and craniosynostosis (each 64%) and failure to thrive (62%). Up to now 20 patients started medical treatment with Asfotase alfa. 

Conclusions 
Reported findings support the clinical perception of HPP being a chronic multi-systemic disease with often delayed diagnosis. Our natural history information provides detailed insights into the prevalence of different symptoms, which can help to improve and shorten diagnostics and thereby lead to an optimised medical care, especially with promising therapeutic options such as enzyme-replacement-therapy with Asfotase alfa in mind.
KW  - hypophosphatasia
KW  - alkaline phosphatase
KW  - asfotase alfa
KW  - rare bone disease
KW  - osteomalacia
KW  - rickets
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-230505
VL  - 15
ER  - 
TY  - JOUR
A1  - Notz, Quirin
A1  - Lotz, Christopher
A1  - Herrmann, Johannes
A1  - Vogt, Marius
A1  - Schlesinger, Tobias
A1  - Kredel, Markus
A1  - Muellges, Wolfgang
A1  - Weismann, Dirk
A1  - Westermaier, Thomas
A1  - Meybohm, Patrick
A1  - Kranke, Peter
T1  - Severe neurological complications in critically ill COVID‑19 patients
JF  - Journal of Neurology
N2  - No abstract available.
KW  - COVID-19
KW  - neurological complications
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-232429
SN  - 0340-5354
ER  -